ÂÜÀòÂÒÂ×

Matthew Osborne currently serves as the Vice President of Investor Relations and Corporate Communications at Zenas BioPharma, a clinical-stage global biopharmaceutical company focused on advancing transformative immunology-based therapies. Prior to this role, Matthew was the Head of Portfolio Company Investor Relations at ATP, a leader in life sciences venture capital. Previous experience includes serving as Chief Financial Officer at Senda Biosciences, OncXerna Therapeutics, and Unum Therapeutics, as well as Vice President positions at Shire, Synageva BioPharma Corp., and Voyager Therapeutics. Matthew began a career in biotechnology as a Biotechnology Equity Analyst at Lazard Capital Markets after obtaining an MBA from D'Amore-McKim School of Business and a Bachelor of Science in Biology from Syracuse University.